Research Article

Effects of Autophagy-Related Genes on the Prognosis and Immune Microenvironment of Ovarian Cancer

Jing Zhang,1 He Yan,2 and Yan Fu1

1Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Xin Min Street 71, 130021 Changchun, China
2Department of Emergency Medicine, The First Hospital of Jilin University, Xin Min Street 71, 130021 Changchun, China

Correspondence should be addressed to He Yan; yanhe@jlu.edu.cn and Yan Fu; f_y@jlu.edu.cn

Received 12 April 2022; Revised 30 June 2022; Accepted 7 July 2022; Published 30 July 2022

Academic Editor: Piotr Gas

Copyright © 2022 Jing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ovarian cancer (OC) is among the most malignant tumors of the female reproductive system. The role of autophagy in cancer is complex, and the functional relationship between autophagy-related genes and OC remains unclear. Here, the prognostic value of autophagy-related genes in OC and relationships between autophagy and immune function were evaluated. OC data from The Cancer Genome Atlas and the Human Autophagy Database were obtained to identify autophagy-related genes. Univariate and multivariate Cox analyses were used to construct a prognostic model based on autophagy-related genes. Relationships between risk scores and clinical traits were evaluated. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Cytoscape were used to analyze gene functions and their effects on the immune microenvironment. Relationships between autophagy genes and long noncoding RNAs (lncRNAs) were evaluated by Pearson’s correlation coefficients, and lncRNAs corresponding to the autophagy-related genes associated with OC prognosis were used to construct a model. Relationships between risk scores and survival and prognosis were evaluated. Finally, a gene set enrichment analysis was performed. Seven autophagy-related genes (CAPN1, CDKN1B, DNAJB1, GNAI3, MTMR14, RHEB, and SIRT2) were identified as independent predictors of prognosis. Three lncRNAs corresponding to autophagy genes independently influenced prognosis. Autophagy genes are closely related to immunity. Fifteen immune cell types showed different levels of infiltration between the high- and low-risk groups. Moreover, immune cell infiltration differed between the high- and low-risk groups based on the model. Our analysis of genes and lncRNAs related to prognosis clarifies the role of autophagy in OC and provides a theoretical basis for further research.

1. Introduction

Ovarian cancer (OC) is the fifth most lethal cancer in women and accounts for more than 150,000 deaths annually worldwide. The mortality rate of OC has increased over the past few years [1, 2]. Despite recent improvements in cytoreductive surgery and chemotherapy, the 5-year survival rate of OC remains approximately 30%–40% owing to late diagnosis and chemoresistance [3, 4].

Long noncoding RNAs (lncRNAs) are defined as nonprotein-coding transcripts more than 200 nucleotides in length and are classified into five categories on the basis of their locations relative to nearby protein-coding genes: (1) sense lncRNAs, (2) antisense lncRNAs, (3) bidirectional lncRNAs, (4) intronic lncRNAs, and (5) intergenic lncRNAs [5]. LncRNAs are essential for general cell functions and play roles in the proliferation, migration, and invasion of cancers, including OC [6, 7].

Autophagy is a degradation pathway that is highly conserved during the evolution of eukaryotes. The formation of a double-layer membrane structure allows the transportation of damaged organelles, misfolded and aggregated proteins, and other macromolecular substances to the lysosome for degradation or recycling [8]. Autophagy plays very complex roles in tumors, including inhibiting or promoting them in different environments and stages of cancer
development [9, 10]. Autophagy is generally beneficial during the normal state of the body and the early stages of tumors, by eliminating oncogenic protein substrates, misfolded proteins, and damaged organelles, maintaining cell homeostasis, and either preventing tumors from occurring or inhibiting their progression [11]. However, once tumor develop to an advanced stage, autophagy—as a dynamic degradation and recycling system—promotes their survival and growth by enhancing the living ability of cancer cells in an environment characterized by nutrient starvation and hypoxia [12, 13]. Numerous studies have found a close link between autophagy and ovarian cancer. However, further research is required to identify the specific autophagy-related genes which are involved. In this study, we have explained the prognostic relationship between autophagy and ovarian cancer.

2. Materials and Methods

2.1. Data Acquisition and Collation. Microarray data and corresponding clinical data were obtained from 380 OC samples from The Cancer Genome Atlas (TCGA). The Human Autophagy Database (http://autophagy.lu/clustering/index.html) was used to identify all genes involved in autophagy. The CytoHubba plug-in of Cytoscape was used to produce and generate a graph showing the correlations between gene expression levels. All mRNA levels were log2-transformed. Pearson’s correlation coefficients were calculated for relationships between gene and lncRNA levels. Values of $|R^2| > 0.3$ and $P < 0.05$ were considered significant.

2.2. Model Construction. A univariate Cox analysis of the autophagy-related genes was carried out using the survival package in R, and genes with $\text{coxPfilter} = 0.05$ were screened out. Then, the COXPH command in R was used to conduct a multivariate Cox analysis of these genes, and the coefficients (i.e., hazard ratios (HR) values) were obtained. The data of the obtained genes were used to construct a model. The risk for each sample was assessed using a risk score. The higher the risk score, the worse the prognosis for the patient, and in contrast, the lower the risk score, the better the prognosis for the patient. The risk score for each sample was obtained by multiplying the coefficient for each gene in the model and taking the sum of these products. TCGA samples were randomly divided into training and test groups, and the median risk score for each group was set as the boundary to divide samples into high- and low-risk groups (see attachment 1 for details). Univariate and multivariate Cox analyses of lncRNAs were performed following similar methods to those used for gene-based analyses.

2.3. Receiver Operating Characteristics (ROC). The survival-ROC package in R was used to analyze the accuracy of the model. The accuracies of the gene-based model and the lncRNA-based model were compared.

2.4. Gene Set Enrichment Analysis (GSEA). GSEA was used to study pathway enrichment in the high- and low-risk groups. After importing the data for high- and low-risk groups, the gene set database (c2.cp.kegg.v7.4.symbols.gmt) was used for gene set permutations, with 1000 permutations to evaluate significance. Meaningful channels were selected, and R packages pplyr, ggplot2, grid, and gridExtra were used to combine pathway results.

2.5. Analysis of Immune Infiltration Using CIBERSORT. CIBERSORT was used to analyze the infiltration of immune cells [14]. Levels of immune cell infiltration in each sample were first calculated using CIBERSORT in R. The infiltration of immune cells was plotted using the limma and ggpubr packages in R.

3. Results

3.1. Construction of an Autophagy-Related Gene Model for Ovarian Cancer. Autophagy-related genes were sorted according to the degree of correlation between expression and prognosis (Figure 1(a), where darker colors indicate stronger correlations) (see attachment 3 for details). Sixteen genes were closely related to prognosis in OC, as determined by univariate Cox analyses: ATG9A, CAPN1, CDKN1B, CXXCR4, DNAJB1, EGF, FADD, GNAI3, IL24, MTMR14, NPC1, PPP1R15A, RB1, RHEB, SNGR1A, and SIRT2 (Figure 1(b), $P \leq 0.05$). A multivariate Cox analysis of the 16 genes revealed that CAPN1, CDKN1B, DNAJB1, GNAI3, MTMR14, RHEB, and SIRT2 were independent factors affecting prognosis. Using the coefficients from the multivariate analysis, these seven autophagy-related genes were used to construct a prognostic model. The purpose of the univariate and multivariate Cox analysis was to determine which autophagy genes were related to ovarian cancer prognosis. In Figure 1, green indicates that the hazard ratio is $<1$ (low risk), indicating that the higher the gene expression value, the better the prognosis of the patient will be. Red corresponds to a hazard ratio $>1$ (high risk), indicating that a higher gene expression value correlates to a worse prognosis (Figures 1(b) and 1(c)).

3.2. Verification of the Autophagy Model. Using the newly established prognostic model, the risk score for each sample was obtained. There were significant differences between patients with high and low risk scores in the training and test groups (Figures 1(d) and 1(e); $P < 0.001$). The accuracy of the model was verified by an ROC analysis; the area under
Figure 1: Continued.
Figure 1: Continued.
the curve (AUC) values for both the training and test groups were greater than 0.5 (0.779 and 0.641, respectively), indicating that the model was reliable (Figures 1(f) and 1(g)). The risk scores for each patient in the two groups are shown in Figures 2(a) and 2(b). Survival was longer in the low-risk group than in the high-risk group (Figures 2(c) and 2(d)). Figures 2(e) and 2(f) summarizes gene expression profiles in the high- and low-risk groups. We studied the expression of genes in the high-risk group and relationship between gene expression levels and risk scores. The expression of levels of CDKN1B, GNAI3, and Sirt2 differed between the high- and low-risk groups, and CDKN1B and Sirt2 levels were positively correlated with the risk score. GNAI3 expression was negatively correlated with the risk score (Figure 2(g)).

3.3. Relationships between the Autophagy Model and Clinical Parameters. Because OC is relatively rare, a univariate analysis including age, grade, and risk score was conducted. Age and risk score had an effect on prognosis in both groups (Figures 3(a) and 3(b)). A multivariate Cox analysis showed that age and risk score in the training group were independent factors affecting prognosis (Figure 3(c), \( P < 0.05 \)), whereas age, grade, and risk score in the test group could not be regarded as independent predictors of prognosis (Figure 3(d)). We further generated a nomogram for the prediction of 1-, 2-, and 3-year survival (Figure 3(e)).

3.4. Effect of lncRNAs Associated with Autophagy-Related Genes on OC. Abnormal lncRNA expression plays a crucial role in tumor development and progression [8]. Thus, we identified lncRNAs related to the 16 autophagy-related genes associated with prognosis in OC (Figure 4) (see attachment 5 for details). By a univariate Cox analysis, we identified 14 lncRNAs (i.e., LINC02088, AC008115.3, AC027309.1, AC136601.1, AL357153.1, AC022144.1, OSTM1-AS1, AC008659.1, PKP4-AS1, LINC02574, AL355516.1, LINC02273, AC010240.3, and AC011445.1) with prognostic values for OC (Figures 5(a), \( P < 0.05 \)). A multivariate Cox analysis of these lncRNAs revealed that AC136601.1, LINC02273, and AC011445.1 could independently predict prognosis (Figure 5(b), Stab. 2). Based on the coefficient for each lncRNA, a risk model was developed. There were significant differences in survival between the groups with high and low risk scores (Figure 5(c), \( P < 0.05 \)). A Sankey diagram was generated for an intuitive representation of the impact of the risk score on prognosis, showing that the mortality rate was significantly higher in the high-risk group than in the low-risk group (Figure 5(d)). To compare the accuracy of the gene-based and lncRNA-based models for risk assessment in OC, we generated ROC curves and found that the AUC values for genes were significantly greater than those for lncRNAs, indicating that the model constructed based on autophagy-related genes could more accurately reflect risk in OC (Figure 5(e)).

3.5. Associations between Immunity and Autophagy-Related Genes. Our results support the prognostic value of the autophagy-related gene model of OC; accordingly, we performed functional enrichment analyses of genes in the model. A Gene Ontology (GO) enrichment analysis revealed that the genes in the model were enriched in the cell cycle process, cell cycle, and cell growth (Figure 6(a)) (see attachment 6 for details). A Kyoto Encyclopedia of Genes and
Figure 2: Continued.
Figure 2: Distribution of risk scores in patients with ovarian cancer. (a and b) Distribution of risk scores in the high and low autophagy groups in training and test sets. The x-axis indicates the patient number, and y-axis indicates the risk score. (c and d) Distribution of survival in the high and low autophagy groups in training and test sets. Dots represent patient status ranked by the increasing risk score. The x-axis shows the patient number, and y-axis shows the survival time. (e and f) Heatmap showing expression levels of seven genes used to construct the autophagy model in the high- and low-risk groups from training and test sets. (g) Expression of seven genes included in the autophagy model in the high- and low-risk groups; relationships between the expression levels of seven genes and risk scores.
|     | p value | Hazard ratio               |
|-----|---------|----------------------------|
| Age | 0.005   | 1.027 (1.008 − 1.046)     |
| Grade| 0.905  | 0.963 (0.518 − 1.792)     |
| Risk score | <0.001 | 1.352 (1.239 − 1.475)     |

(a)

|     | p value | Hazard ratio               |
|-----|---------|----------------------------|
| Age | 0.022   | 1.020 (1.003 − 1.038)     |
| Grade| 0.097  | 1.534 (0.926 − 2.541)     |
| Risk score | 0.032 | 1.082 (1.007 − 1.164)     |

(b)

|     | p value | Hazard ratio               |
|-----|---------|----------------------------|
| Age | 0.010   | 1.025 (1.006 − 1.044)     |
| Grade| 0.944  | 1.023 (0.546 − 1.916)     |
| Risk score | <0.001 | 1.338 (1.227 − 1.459)     |

(c)

|     | p value | Hazard ratio               |
|-----|---------|----------------------------|
| Age | 0.057   | 1.017 (0.999 − 1.035)     |
| Grade| 0.100  | 1.537 (0.921 − 2.564)     |
| Risk score | 0.109 | 1.062 (0.987 − 1.143)     |

(d)

Figure 3: Continued.
Figure 3: Prognostic value of the autophagy risk signature in ovarian cancer. (a and b) Univariate Cox analysis of the effects of age, grade, and risk score on prognosis in ovarian cancer in the training and test groups. (c and d) Multivariate Cox analysis of age, grade, and risk score for the identification of independent risk factors for ovarian cancer in the training and test groups. (e) Nomogram showing the predictive value of the autophagy model for survival at 1, 2, and 3 years.

Figure 4: Autophagy genes related to ovarian cancer prognosis (shown in yellow) and corresponding lncRNAs (shown in blue). lncRNAs: long noncoding RNAs.
| p value | Hazard ratio |
|---------|--------------|
| **LINC02088** | <0.001 3.394 (1.710 – 6.736) |
| **AC008115.3** | 0.033 1.267 (1.019 – 1.576) |
| **AC027309.1** | 0.005 5.506 (1.659 – 18.278) |
| **AC136601.1** | <0.001 23.390 (4.598 – 118.987) |
| **AL357153.1** | 0.003 5.440 (1.766 – 16.758) |
| **AC022144.1** | 0.027 1.085 (1.009 – 1.166) |
| **OSTM1–AS1** | <0.001 1.580 (1.269 – 1.967) |
| **AC008659.1** | 0.004 7.410 (1.864 – 29.461) |
| **PKP4–AS1** | 0.001 5.338 (1.911 – 14.908) |
| **LINC02574** | <0.001 1.065 (1.032 – 1.099) |
| **AL355516.1** | 0.008 2.338 (1.246 – 4.386) |
| **LINC02273** | 0.022 0.104 (0.015 – 0.723) |
| **AC010240.3** | 0.032 2.340 (1.076 – 5.093) |
| **AC011445.1** | 0.012 1.111 (1.024 – 1.205) |

Figure 5: Continued.
\[ p = 0.002 \]

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5_c}
\caption{Continued.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5_d}
\caption{Continued.}
\end{figure}
Genomes (KEGG) enrichment analysis revealed that the genes were involved in pathways related to prostate cancer, gastric cancer, bladder cancer, and other tumor types as well as various immune processes, such as chronic myeloid leukemia, viral protein interaction with cytokine and cytokine receptors, and leukocyte transtumor (Figure 6(b)). A Cytoscape analysis revealed positive regulation of the macrophage migration inhibitory factor signaling pathway and C-C chemokine receptor activity, CXCL12-activated CXCR4 signaling pathway, and other immune-related processes (Figure 6(c)). A GSEA revealed enrichment for apoptosis, hypoxia, IL-2-STAT5 signaling, IL-6-JAK-STAT3 signaling, and other signaling pathways (Figure 6(d)), all of which are related to immunity.

3.6. Relationship between the Autophagy Model and the Immune Microenvironment. Our functional enrichment analyses suggested that there is a close relationship between the model and immunity; therefore, we studied immune cell infiltration in low- and high-risk groups (Figure 7(a)). Levels of infiltration of B cells, CD8+ T cells, dendritic cells (DCs), interdigitating cells (IDCs), macrophages, mast cells, neutrophils, natural killer (NK) cells, plasmacytoid dendritic cells (PDcs), T helper cells, T follicular helper (Tfh) cells, Th1 cells, Th2 cells, tumor-infiltrating lymphocytes (TILs), and Tregs differed between groups (Figure 7(b)). There were significant differences in antigen presenting cell (APC) costimulation, CCR, checkpoint, cytolytic activity, human leukocyte antigen (HLA), inflammation promotion, inflammation, T cell costimulation, T cell costimulation, and type II IFN response in the immune processes (Figure 7(c)).

4. Discussion

Autophagy is a tightly regulated and highly conserved lysosomal degradation pathway [15]. The response of autophagy to homeostasis plays an important role in mammalian development and differentiation [16]. The absence or dysregulation of autophagy is associated with a variety of diseases [17]. We examined the effects of autophagy on OC. We first screened autophagy-related genes related to OC prognosis by a Cox regression analysis to build a predictive model. Some of the genes included in these models are closely related to the occurrence and development of OC based on the previous studies. For example, CAPN1 is the target of adhesion-associated protein hydrolysis [18]. In OC, BRCA1 affects the migration of tumor cells by regulating CAPN1 [19] and plays an important role in double-stranded DNA damage repair via its interaction with SIRT2 [20]. Li and Tang found that low levels of CDKN1B are associated with a poor prognosis in epithelial ovarian carcinoma [21]. GNAI3 is involved in the immune pathway in OC [22]. DNAJB1 and RHEB expressions have also been reported to be affected in OC [23, 24]. However, the role of MTMR14 in OC has not been reported, and further studies on this gene are needed.

OC is currently diagnosed by ultrasound combined with serum tumor marker analysis [25]. However, the specificity of this method is low, with a 5-year survival rate of only 30%–40% [26]. Therefore, more effective tumor markers are needed to improve the early detection rate of OC. We observed a significant difference in survival between the high- and low-risk groups based on our newly developed
Positive regulation of cell cycle process
Positive regulation of cell cycle
Regulation of cell growth
Regulation of mitotic cell cycle phase transition
Regulation of mitotic nuclear division
Negative regulation of transcription from RNA polymerase II promoter in response to stress
Regulation of exit from mitosis
Positive regulation of superoxide anion generation
Regulation of superoxide anion generation
Midbody
Juxtaparanoda region of axon
Schmidt–lantersman incisure
Nuclear cyclin–dependent protein kinase holoenzyme complex
Cul4A–ring E3 ubiquitin ligase complex
Paranode region of axon
Meiotic spindle
Compact myelin
Sperm head
Zymogen granule
Ubiquitin protein ligase binding
Ubiquitin–like protein ligase binding
Hsp70 protein binding
Virus receptor activity
Exogenous protein binding
Ubiquitin binding
ATPase binding
Ubiquitin–like protein binding
Chaperone binding
Heat shock protein binding

Cushing syndrome
Human cytomegalovirus infection
Prostate cancer
Endocrine resistance
Gastric cancer
Chemical carcinogenesis – receptor activation
Human papillomavirus infection
Bladder cancer
Melanoma
Non–small cell lung cancer
Glioma
Pancreatic cancer
Chronic myeloid leukemia
ErbB signaling pathway
Gap junction
Small cell lung cancer
Viral protein interaction with cytokine and cytokine receptor
Parathyroid hormone synthesis, secretion and action
HIF–1 signaling pathway
Leukocyte transendothelial migration
Cell cycle
Relaxin signaling pathway
FoxO signaling pathway
Estrogen signaling pathway
Breast cancer
Oxytocin signaling pathway
Cellular senescence
Hepatitis C
JAK–STAT signaling pathway
Hepatocellular carcinoma

Figure 6: Continued.
Protein kinase C activity
Positive regulation of prolactin secretion
Positive regulation of cyclin-dependent protein kinase activity
Positive regulation of cyclin-dependent protein kinase activity by calmodulin signaling
Positive regulation of production of small RNA involved in gene silencing by miRNA
Tubulin deacetylase activity
Histone deacetylase activity (H4-K16 specific)
Positive regulation of oocyte maturation
Negative regulation of transcription from RNA polymerase II promoter in response to hypoxia
NAD-dependent histone deacetylase activity (H4-K16 specific)
Regulation of macrophage differentiation
Positive regulation of macrophage migration inhibitory factor signaling pathway
Positive regulation of mitotic sister chromatid segregation
Negative regulation of transcription from RNA polymerase II promoter in response to stress
Mitotic sister chromatid cohesion
Negative regulation of tau protein kinase activity
Regulation of dendrite extension
Positive regulation of dendrite extension
CXCL12–activated CXCR4 signaling pathway
C–X–C motif chemokine 12 receptor activity
Positive regulation of oligodendrocyte differentiation
C–X–C motif chemokine 12 receptor activity
CXCL12–activated CXCR4 signaling pathway
Negative regulation of transcription involved in G1/S transition of mitotic cell cycle
Regulation of exit from mitosis
Positive regulation of proteasomal ubiquitin–dependent protein catabolic process involved in cellular response to hypoxia
Activation of phospholipase A2 activity by calcium-mediated signaling
Activation of phospholipase A2 activity
EGFR
CDKN1B
DNAJB1
RB1
CXCR4
Regulation of production of miRNAs involved in gene silencing by miRNA
Regulation of production of small RNA involved in gene silencing by RNA
Astrocyte activation
Negative regulation of cardiocyte differentiation
SIRT2
(c)
0.2
0.0
Enrichment score
−0.2
High expression Low expression
HALLMARK_APOPTOSIS
HALLMARK_HYPOXIA
HALLMARK_R2_STATS_SIGNALING
HALLMARK_R6_EAK_STATS_SIGNALING
HALLMARK_INFLAMMATORY_RESPONSE
HALLMARK_P53_PATHWAY
HALLMARK_PKD_MTOR_SIGNALING
HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
(d)
Figure 6: Functional enrichment analysis of autophagy genes included in the predictive model. (a) GO enrichment analysis of the autophagy model. (b) KEGG enrichment analysis of the autophagy model. (c) Cytoscape analysis of pathways related to genes in the model. (d) GSEA of pathway enrichment. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSEA: gene set enrichment analysis.
Figure 7: Continued.
predictive model. Furthermore, the accuracy was verified by an ROC curve analysis (AUC > 0.6), supporting its potential use for the early detection of OC. Combinations of biomarkers can improve detection efficiency over those of single markers [27, 28]. To further study the prognostic value of the model, we included clinical parameters in regression analyses and found that the model is an indicator for predicting prognosis, similar to age; however, in a multivariate Cox analysis of the test group, age, grade, and model were not statistically significant. This may be related to the small sample size. Most patients in the sample were classified as grade 2 or 3, whereas only a few patients were classified as grade 1 or 4, making it difficult to accurately evaluate the impact of grade on prognosis. Based on the model, we drew a nomogram, providing a tool for the individualized evaluation of prognosis.

IncRNAs play important roles in all stages of gene expression [29]. A previous study has confirmed that IncRNAs can be used as prognostic biomarkers for OC [30]. Therefore, we screened IncRNAs related to autophagy-related genes and identified IncRNAs related to OC prognosis by univariate and multivariate analyses. In addition to AC011445.1, the three IncRNAs used for modeling have been associated with OC [31], and the other two have not yet been reported in OC. Using the model based on IncRNAs, there were significant differences in prognosis between the high- and low-risk groups. These results indicate that the IncRNA-based model can be used as a biomarker to predict the prognosis in OC. We compared models constructed based on autophagy-related genes and IncRNAs and found that the accuracy of the gene-based model was higher. This comparison is helpful for the selection of effective tumor markers for the early diagnosis of OC in the future.

To gain a deeper understanding of the model constructed by autophagy-related genes, we performed pathway enrichment analyses. The P53 and PI3K-Akt-mTOR pathways play important roles in the activation and regulation of autophagy [32, 33]. Other pathways, involving inflammatory cells, IL2-STAT5, and IL-6-JAK-STAT3, are mainly associated with inflammation and immunity. In fact, OC cells release cytokines to recruit activated stromal fibroblasts and immune cells, leading to inflammatory infiltration in the stroma. This, in turn, impedes the immune response and promotes the proliferation of tumor cells. Wang et al. found that several products of OC inhibit the expression of IL-2Rβ, γ, and JAK3, as well as the phosphorylation of STAT5 tyrosine in T cells, thereby inducing immunosuppression in OC [34]. In our study, we also found obvious differences in the activation of cytolytic and inflammation-promoting functions between the high- and low-risk groups. A large number of studies have shown that autophagy is a key regulator of the natural immunity in tumor cells [35]. For example, autophagy can affect IL-1-dependent secretory processes via IL-17, IFN-γ, and IL-22 signaling [36]. Autophagy can also regulate T and B lymphocytes and plays an important role in the activation, metabolism, and proliferation of T cells [32, 37]. This is consistent with our results, indicating...
significant differences in the infiltration of B cells and multiple T cell subsets between the high- and low-risk groups. Autophagy is also closely related to apoptosis and hypoxia. The relationship between autophagy and apoptosis is subtle. During chemotherapy, autophagy can protect tumor cells from apoptosis and eventually result in drug resistance [38]. Excessive autophagy can also lead to apoptosis. In the process of hypoxia, tumor cells use autophagy to undergo metabolic reprogramming to obtain the energy needed for survival [38].

5. Conclusions

In our study, we evaluated the effect of autophagy on prognosis in OC and explored the functions of autophagy. These findings provide direction for the identification of additional tumor markers, including lncRNAs related to the prognosis, and for analyses of the mechanisms underlying the effect of autophagy on OC. A limitation of this study is that the sample size was small and data were obtained from a single database; therefore, a larger sample size and more data are needed to verify the prognostic value of our model. In addition, our results need to be confirmed in large-scale clinical trials. These follow-up studies are expected in the near future.

Data Availability

The data supporting the findings of this study are available in the Cancer Genome Atlas (TCGA) and the Human Autophagy Database (http://autophagy.lu/clustering/index .html).

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Jing Zhang designed the experiment and drafted the manuscript. Yan Fu contributed to the study design and gave the theoretical guidance. He Yan contributed to the statistical analyses. Yan Fu was responsible for the revision of the final version. All authors read and approved the final manuscript.

References

[1] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: a Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: a Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015.
[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: a Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
[4] D. Nasioudis, G. Sisti, T. T. Kanninen et al., “Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study,” Gynecologic Oncology, vol. 141, no. 1, pp. 128–133, 2016.
[5] J. L. Rinn and H. Y. Chang, “Genome regulation by long non-coding RNAs,” Annual Review of Biochemistry, vol. 81, no. 1, pp. 145–166, 2012.
[6] T. Worku, D. Bhattarai, D. Ayers et al., “Long non-coding RNAs: the new horizon of gene regulation in ovarian cancer,” Cellular Physiology & Biochemistry, vol. 44, no. 3, pp. 948–966, 2017.
[7] L. L. Fu, C. J. Li, Y. Xu et al., “Role of lncRNAs as novel biomarkers and therapeutic targets in ovarian cancer,” Critical Reviews in Eukaryotic Gene Expression, vol. 27, no. 2, pp. 183–195, 2017.
[8] K. R. Parzych and D. J. Klinosky, “An overview of autophagy: morphology, mechanism, and regulation,” Antioxidants & Redox Signaling, vol. 20, no. 3, pp. 460–473, 2014.
[9] S. Turcotte and A. J. Giaccia, “Targeting cancer cells through autophagy for anticancer therapy,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 246–251, 2010.
[10] X. Li, S. He, and B. Ma, “Autophagy and autophagy-related proteins in cancer,” Molecular Cancer, vol. 19, no. 1, 2020.
[11] E. White, C. Karp, A. M. Strohecker, Y. Guo, and R. Mathew, “Role of autophagy in suppression of inflammation and cancer,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 212–217, 2010.
[12] R. Amaravadi, A. C. Kimmelman, and E. White, “Recent insights into the function of autophagy in cancer,” Genes & Development, vol. 30, no. 17, pp. 1913–1930, 2016.
[13] J. M. Levy, C. G. Towers, and A. Thorburn, “Targeting autophagy in cancer,” Nature Reviews Cancer, vol. 17, no. 9, pp. 528–542, 2017.
[14] W. Lin, S. Wu, X. Chen et al., “Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups,” Frontiers in Oncology, vol. 10, p. 796, 2020.
[15] L. Devis-Jauregui, N. Eritja, M. L. Davis, X. Matias-Guiu, and D. Llobet-Navás, “Autophagy in the physiological endometrium and cancer,” Autophagy, vol. 17, no. 5, pp. 1077–1095, 2021.
[16] N. Mizushima and B. Levine, “Autophagy in mammalian development and differentiation,” Nature Cell Biology, vol. 12, no. 9, pp. 823–830, 2010.
[17] T. Wollert, “Autophagy,” Current Biology, vol. 29, no. 14, pp. R671–R677, 2019.
[18] N. Dourdin, A. K. Bhatt, P. Dutt et al., “Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts,” Journal of Biological Chemistry, vol. 276, no. 51, pp. 48382–48388, 2001.
[19] D. M. Gau, J. L. Lesnock, B. L. Hood et al., “BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - a proteomics study,” Cell Cycle, vol. 14, no. 12, pp. 1884–1892, 2015.
[20] E. Minten, H. Zhang, C. Li, P. M. Head, and D. S. Yu, “Abstract 1751: The role of SIRT2 in BRCA1 regulation,” Cancer Research, vol. 79, 13_Supplement, p. 1751, 2019.
[21] X. Li and M. Tang, “Exosomes released from M2 macrophages transfer miR-221-3p contributed to EOC progression through targeting CDKN1B,” Cancer Medicine, vol. 9, no. 16, pp. 5976–5988, 2020.
[22] P. K. P. Krishnamoorthy, M. A. Kamal, M. K. Warsi et al., “In-silico study reveals immunological signaling pathways, their
genes, and potential herbal drug targets in ovarian cancer,” *Informatics in Medicine Unlocked*, vol. 20, p. 100422, 2020.

[23] I. S. Goldlust, K. Wilson, L. Szabova et al., “Abstract 278: no cell left behind: residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol,” *Cancer Research*, vol. 76, 14_Supplement, p. 278, 2016.

[24] M. K. Altman, A. A. Alshamrani, W. Jia et al., “Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells,” *Cancer Letters*, vol. 369, no. 1, pp. 175–183, 2015.

[25] V. Rojas, K. M. Hirshfield, S. Ganesan, and L. Rodriguez-Rodriguez, “Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment,” *International Journal of Molecular Sciences*, vol. 17, no. 12, p. 2113, 2016.

[26] S. Nimmagadda and M. F. Penet, “Ovarian cancer targeted theranostics,” *Frontiers in Oncology*, vol. 9, p. 1537, 2020.

[27] Y. S. Kim, M. K. Jang, C. Y. Park, H. J. Song, and J. D. Kim, “Exploring multiple biomarker combination by logistic regression for early screening of ovarian cancer,” *International Journal of Bio-Science and Bio-Technology*, vol. 5, no. 4, pp. 215–222, 2013.

[28] T. R. Mercer and J. S. Mattick, “Structure and function of long noncoding RNAs in epigenetic regulation,” *Nature Structural & Molecular Biology*, vol. 20, no. 3, pp. 300–307, 2013.

[29] M. Zhou, X. Wang, H. Shi et al., “Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer,” *Oncotarget*, vol. 7, no. 11, pp. 12598–12611, 2016.

[30] C. Meng, J. Q. Zhou, and Y. S. Liao, “Autophagy-related long non-coding RNA signature for ovarian cancer,” *Journal of International Medical Research*, vol. 48, no. 11, 2020.

[31] H. Pan, L. Chen, Y. Xu et al., “Autophagy-associated immune responses and cancer immunotherapy,” *Oncotarget*, vol. 7, no. 16, pp. 21235–21246, 2016.

[32] T. Shintani and D. J. Klionsky, “Autophagy in health and disease: a double-edged sword,” *Science*, vol. 306, no. 5698, pp. 990–995, 2004.

[33] H. Wang, X. Xie, W. G. Lu et al., “Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor β and γ expression and their JAK-STAT signaling pathway,” *Life Sciences*, vol. 74, no. 14, pp. 1739–1749, 2004.

[34] C. Gerada and K. M. Ryan, “Autophagy, the innate immune response and cancer,” *Molecular Oncology*, vol. 14, no. 9, pp. 1913–1929, 2020.

[35] C. Peral de Castro, S. A. Jones, C. N. Cheallaigh et al., “Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion,” *Journal of Immunology*, vol. 189, no. 8, pp. 4144–4153, 2012.

[36] W. Jia, H. H. Pua, Q. J. Li, and Y. W. He, “Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes,” *Journal of Immunology*, vol. 186, no. 3, pp. 1564–1574, 2011.

[37] Y. Dai and S. Grant, “BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance,” *Autophagy*, vol. 11, no. 2, pp. 416–418, 2015.